Sansure Biotech Inc - Asset Resilience Ratio

Latest as of September 2025: 1.50%

Sansure Biotech Inc (688289) has an Asset Resilience Ratio of 1.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sansure Biotech Inc debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥141.90 Million
≈ $20.76 Million USD Cash + Short-term Investments

Total Assets

CN¥9.46 Billion
≈ $1.38 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Sansure Biotech Inc's Asset Resilience Ratio has changed over time. See net assets of Sansure Biotech Inc for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Sansure Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sansure Biotech Inc (688289) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥141.90 Million 1.5%
Total Liquid Assets CN¥141.90 Million 1.50%

Asset Resilience Insights

  • Limited Liquidity: Sansure Biotech Inc maintains only 1.50% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Sansure Biotech Inc Industry Peers by Asset Resilience Ratio

Compare Sansure Biotech Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Caina Technology Co. Ltd.
SHE:301122
Medical Instruments & Supplies 23.52%
Mark Dynamics Indonesia Tbk PT
JK:MARK
Medical Instruments & Supplies 6.64%
GETS Global Bhd
KLSE:5079
Medical Instruments & Supplies 0.03%
QITIAN Technology Group Co Ltd
SHE:300061
Medical Instruments & Supplies 0.00%
Sartorius Aktiengesellschaft
XETRA:SRT3
Medical Instruments & Supplies 4.48%
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Medical Instruments & Supplies 29.19%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 4.42%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 51.82%

Annual Asset Resilience Ratio for Sansure Biotech Inc (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Sansure Biotech Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.62% CN¥139.67 Million
≈ $20.44 Million
CN¥8.60 Billion
≈ $1.26 Billion
-4.86pp
2023-12-31 6.49% CN¥548.28 Million
≈ $80.23 Million
CN¥8.45 Billion
≈ $1.24 Billion
-20.23pp
2022-12-31 26.72% CN¥2.45 Billion
≈ $358.69 Million
CN¥9.17 Billion
≈ $1.34 Billion
-2.14pp
2021-12-31 28.86% CN¥2.05 Billion
≈ $299.46 Million
CN¥7.09 Billion
≈ $1.04 Billion
-0.49pp
2020-12-31 29.36% CN¥1.60 Billion
≈ $234.31 Million
CN¥5.45 Billion
≈ $798.15 Million
+19.03pp
2019-12-31 10.32% CN¥66.33 Million
≈ $9.71 Million
CN¥642.47 Million
≈ $94.01 Million
--
pp = percentage points

About Sansure Biotech Inc

SHG:688289 China Medical Instruments & Supplies
Market Cap
$1.45 Billion
CN¥9.94 Billion CNY
Market Cap Rank
#7518 Global
#1817 in China
Share Price
CN¥17.15
Change (1 day)
-1.55%
52-Week Range
CN¥17.13 - CN¥22.94
All Time High
CN¥81.40
About

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more